logo

  Core Connection
  Aug. 1 - Oct. 31, 2013


www.cancer.uci.edu/shared_resources.asp
 In This Issue 


Shared Resources
  Biobehavioral
  Biostatistics
  Experimental Tissue Resource
  Genomics High-Throughput
  In-Vivo Onco-Imaging
  Optical Biology Core
  Transgenic Mouse Facility
 
  
Other Items
  Contact Us
  Did You Know?
  Don't Forget
  Funding Opportunities
  Social Networking Tools
  You Are Invited...


Research Programs
Our research efforts are organized into four research programs, which serve to foster interactions and collaborations within specific themes. Cancer center members are affiliated with one program but work with collaborators from different programs in multidisciplinary groups.

The Chao Family Comprehensive Cancer Center's four research programs are:

Cancer Prevention & Prognosis (CPP)
Chemical & Structural Biology (CSB)
Onco-Imaging & Biotechnology (OIB)
Systems, Pathways & Targets (SPT)


In addition, the cancer center has Associate Members (AS)
.

  Don't Forget

Employee Bulletin
Federal funding that maintains support for cancer center cores (and keeping prices low) depends critically on papers published that use our center facilities. As NIH transitions to digital, it becomes critically important that you list the support of the Cancer Center Support Grant (CCSG) in all appropriate publications. Verification of acknowledgment of support will come from electronically scanned publications. It is essential to cite the CCSG if your publication is cancer-related and supported by the center, such as: "Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number P30CA062203. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”

 Countdown to the CCSG
 Competing Application

Calendar

days until the Cancer Center Support Grant (CCSG) competing application is due, Jan. 25, 2015.
 Did You Know?  

?
In 2012, more than 300 cancer center members and non-members used our shared resources. Our shared resources provide services and support essential to basic and translational research at UC Irvine and beyond.

 You Are Invited...  

Invitation

Women's DOT Meeting
Jan. 17, 11:30 a.m.
UC Irvine Medical Center
Building 3, Room 101


Prostate DOT Meeting
Jan. 22, 4 p.m.
UC Irvine Medical Center
Building 3, Room 101

Skin DOT Meeting
Jan. 27, 1 p.m.
UC Irvine campus, SPH 105

Colon DOT Meeting
Jan. 28, 5 p.m.
UC Irvine Medical Center
Douglas Hospital, Room 3636

Women's DOT Meeting
Feb. 21, 11:30 a.m.
UC Irvine Medical Center
Building 56, Room 113

Skin DOT Meeting
Feb. 24, 6 p.m.
UC Irvine Medical Center
Building 23, Room 402

Colon DOT Meeting
Feb. 25, 5 p.m.
UC Irvine Medical Center
Douglas Hospital, Room 3636

Prostate DOT Meeting
Feb. 26, 4 p.m.
UC Irvine Medical Center
Building 3, Room 101

Women's DOT Meeting
Mar. 21, 11:30 a.m.
UC Irvine Medical Center
Building 55, Room 212

Skin DOT Meeting
Mar. 24, 1 p.m.
UC Irvine campus, BLI Library

Colon DOT Meeting
Mar. 25, 5 p.m.
UC Irvine Medical Center
Douglas Hospital, Room 3636

Prostate DOT Meeting
Mar. 26, 4 p.m.
UC Irvine Medical Center
Building 3, Room 101


 Funding Opportunities  


$

Internal Funding Opportunities
Please contact:
Jacqueline Tidball
Associate Director, CCSG Administration
tidball@uci.edu

External Funding Opportunities
The cancer center’s extramural awards analyst provides services that include identifying federal and private funding opportunities and discovering project-specific funding sources, in addition to timely editorial and proposal writing support.

Please contact:
Alisz Demecs
Extramural Awards Analyst
ademecs@uci.edu

 Social Networking Tools  

Facebook Twitter
Like us on Facebook or follow us on Twitter!

 Contact Us  

Email
The Chao Family Comprehensive Cancer Center supports seven shared resources that provide services essential to basic and translational research. Each of these is available to researchers at UC Irvine and other institutions. Investigators do not have to be cancer center members to use the facilities. Each shared resource is partially funded by user fees and other support. To learn more about the services offered and how they might benefit your research, please refer to the specific contact information listed under the shared resource section of this newsletter or contact:

Jacqueline Tidball
Associate Director, CCSG Administration
tidball@uci.edu

Jennifer Ivask
Community Engagement Manager
jivask@uci.edu



 Biobehavioral Shared Resource Facility (BBSR)

Wenzel Director: Lari Wenzel, PhD
Phone:
949-824-3926
Manager:
Susie Hsieh, PhD
Phone:
949-824-3384
Location:
UC Irvine, 212 Sprague Hall, Irvine, CA 92697
www.cancer.uci.edu/resources/biobehavioral.asp

The goal of the BBSR is to support cancer researchers by providing them with the necessary expertise and assistance to incorporate patient/participant-reported outcomes (PROs), health-related quality-of-life (QOL) and counseling interventions. The BBSR participates in translational research in psychoneuroimmunology, examination of behavioral issues that enhance recruitment and compliance within cancer center clinical trials and development of behavioral and QOL outcomes associated with clinical trials. The primary activities of the BBSR include: consultation on behavioral and/or QOL self-report measurement, research design, data collection, interpretation of self-report data, manuscript preparation and counseling interventions within clinical trials.

gray bar
Quarterly Highlights
The BBSR continues to collaborate with peer-reviewed full members of the cancer center. Patient-reported outcomes data analyses, as well as biomarker analyses, continued for the NIH-funded R01 project entitled, “Stress, Immunity and Cervical Cancer: Biobehavioral Outcomes of a Randomized Clinical Trial,” [Nelson, co-PI/Onco-Imaging & Biotechnology (OIB); Wenzel, co-PI/Cancer Prevention & Prognosis (CPP)]. Recruitment is finished and the study is closed to enrollment at 204 patients. Analyses of data will be ongoing.



 Biostatistics Shared Resource Facility (BSR)

Gillen Director: Daniel L. Gillen, PhD
Phone: 949-824-9862
Facility Manager: Michael J. Phelan, PhD
Phone: 949-824-9637

Location:
101 The City Drive South, Bldg. 56, Rm. 228, Orange, CA 92868

www.cancer.uci.edu/biostatistics/index.asp

The mission of the BSR faculty and staff is to support the conception, design, implementation, analysis and reporting of research conducted by members of the Chao Family Comprehensive Cancer Center.

gray bar
Quarterly Highlights
The BSR assisted with new project development and peer review agency submissions. The core held frequent meetings to coordinate shared resource development and to discuss statistical activities.



 Experimental Tissue
 Shared Resource Facility (ETR)

Edwards Director: Robert Edwards, MD, PhD
Phone: 949-824-8576
Facility Manager: Kehui Wang
Phone: 949-824-8974

Location: UC Irvine, Medical Science Building I, D-440, Irvine, CA 92697
www.cancer.uci.edu/resources/experimental_tissue.asp


The primary objective of the ETR is to provide basic, translational and clinical cancer center researchers access to, and analysis of, human and animal tissues.

gray bar
Quarterly Highlights
The ETR continues to provide histology, genotyping, image analysis and laser capture micro-dissection. Histology services were again the most frequently used component, with 23 cancer center users, including 16 full members with peer-reviewed funding. Quarter 3, 2013 was marked by continued increases in the amount of consultation time spent with new and established clients, reviewing proposals for projects that will utilize ETR services and discussing new services, such as production of tissue microarrays.

Learn More

 Genomics High-Throughput Facility (GHTF) 

Sandmeyer Director: Suzanne Sandmeyer, PhD
Phone: 949-824-7571
Facility Manager: Melanie Oakes, PhD
Phone: 949-824-6023
Bioinformatics Director: Chad Garner, PhD
Phone: 949-824-2036

Location: UC Irvine, 340 Sprague Hall, Irvine CA 92697
www.cancer.uci.edu/resources/genomic.asp

The mission of the GHTF is to provide genome-wide analysis for clients interested in gene expression, regulation of gene expression and genome sequence and variation. The primary forms of genome-wide analysis are the Affymetrix GeneChip, Illumina HiSeq 2500 next-generation sequencing and PacBio RS real-time single molecule sequencing.

gray bar
Quarterly Highlights
The Illumina HiSeq 2500 with dual mode capability is our next generation sequencing (NGS) technology. The NGS projects for cancer center members amounted to approximately half of the total sequencing projects performed by GHTF during this reportable quarter and included projects from the laboratories of the following:
  • Kyoko Yokomori, PhD, (SPT)
  • Sergei Grando, MD, PhD, (CPP)
  • Ellis Levin, MD, (SPT)
  • Jefferson Chan, MD, PhD, (SPT)
  • Michael McClelland, PhD, (CPP)

Grando’s project was the targeted resequencing of 17 nicotinic acid receptors in cancer patients. This study utilized the Agilent SureSelect enrichment by capture technology.

Learn More

 In-Vivo Functional Onco-Imaging (IVFOI) 

GulsenDirector: Gultekin Gulsen, PhD
Phone:
949-824-6001
Facility Manager:
TBD
Phone:
949-824-6001
Location: UC Irvine, 164 Irvine Hall, Irvine, CA 92697
www.cancer.uci.edu/resources/in_vivo.asp


The longterm goal of the IVFOI core is to promote the application of imaging techniques in cancer research. Toward this aim, the development and application of imaging technologies are key research areas. The current imaging facilities at the center include:

  • A 15-cm bore 7-Tesla MR system (small animals)
  • A 94-cm bore 4-Tesla MR system (human/small animals)
  • A 57-cm bore 3-Tesla MR system (humans)
  • A combined MR-Diffuse Optical Tomography (MR-DOT) system (small animals)
  • A whole-body positron emission tomography (PET) system (humans)
All combined multimodality systems were developed in-house.

gray bar
Quarterly Highlights
Dr. Leslie Randall's (SPT) research focuses on an FDA-approved angiogenesis inhibitor, Bevacizumab, a drug that slows the growth of new blood vessels. The MRI-SPECT technology developed by the IVFOI Shared Resource is one of a kind in the world and can perform nuclear imaging SPECT inside the MRI thus enabling researchers to perform simultaneous MRI (anatomic and functional) and SPECT (metabolic). This unique imaging instrument will also enable the IVFOI to help Randall study the biology of her orthotopic ovarian cancer model and its response to treatment non invasively.

Learn More

 Optical Biology Core (OBC) 

Marsh Director: J. Lawrence Marsh, PhD
Phone:
949-824-6677
Facility Manager:
Adeela Syed
Phone:
949-824-3226
Location:
UC Irvine, 5302 Biological Sciences II, Irvine, CA 92697
www.cancer.uci.edu/resources/optical_biology_core.asp

The OBC is comprised of three components: (1) The self-use facility located in 4443 McGaugh Hall at the UC Irvine Campus houses a Zeiss LSM 780 and a LSM 700 that can image live cells, fixed samples, model organisms, single molecules and anything in between. For example,a two photon laser is utilized for deep tissue imaging and single photon lasers for imaging all fluorophores from DAPI (405nm) to far red (633nm). The Fluorescence Lifetime Microscopy (FLIM) detector for studying molecules based on their fluorescence lifetime provides a way of studying metabolic states of cancer cells compared to normal cells. Volocity image analysis software is available on a high-end work station for use from an office computer. Training is provided and targeted workshops occur routinely. Users can sign up for time on the scopes 24 hours a day, 7 days a week. (2) The Laer Microbeam and Medical Program (LAMMP) facility located in the Beckman Laser Institute and Medical Clinic is available for collaborative use and protocol development using a number of microscopes. Information about the capabilities can be found at http://lammp.bli.uci.edu/. Some of their capabilities include Mobile Device Management (MDM) platforms for studying skin carcinomas and techniques to detect early melanoma non invasively. (3) A flow cytometry facility is available in Hewitt Hall and contains a MoFlo Cytomation and B-D FACScalibur cytometer. Contact information for the facility can be found at http://dbc.bio.uci.edu/FlowCytoHome.html.

gray bar
Quarterly Highlights
Over the period of August 2013— October 2013, the OBC held two workshops on SuperResolution and FLIM. SuperResolution is a system capable of resolution down to 20 nanometers. Leica brought their system for a demonstration, and center members were able to image their samples. The FLIM workshop was taught by Michelle Digman, PhD, (AS) and Felix Grun, PhD, to educate users on the benefits and uses of our newly-installed FLIM box. The Flow Cytometry Facility will continue to closely support the user community in flow cytometry services, and the LAMMP plans to expand capabilities of core instrumentation, improve the use of their shared systems on-line scheduling and project database.

Learn More

 Transgenic Mouse Facility (TMF) 

RandallDirector: Grant MacGregor, PhD
Phone:
949-824-8253
Facility Manager:
Tom Fielder
Phone:
949-824-6496

Location:
UC Irvine, Biological Sciences III, Rm. B138, Irvine, CA 92697
www.cancer.uci.edu/resources/transgenic_mouse_facility.asp

The TMF assists in the use of genetically-modified mice in biological and biomedical research. An important goal of the TMF is to identify new technology and methodology that is likely to benefit UC Irvine investigators using mice in their research programs and to import and provide such technology to UC Irvine investigators. The TMF makes investigators aware of new and existing developments via the TMF website, in seminars and lectures, via the UC Irvine mouse users email list and by word-of-mouth.

gray bar
Quarterly Highlights
The TMF has continued to develop their strategic plan to relocate the TMF manager’s office, cell culture suite and sperm cryopreservation suite to the second floor of BioSci3, which will improve the TMF’s efficiency and bio-security of its mice. The TMF has been granted “Approved Vendor” status by UCLA and UCSC, and we are pursuing this status at other institutions in California, including UCR and UCSB. This will make it much easier and less expensive for clients at these institutions to obtain transgenic founders and chimeras from us and should increase the demand for TMF services at these institutions.

Learn More